How Has the Kidney Disease Market Evolved Historically and What is its Current Size?
The kidney disease market has seen considerable growth due to a variety of factors.
•In recent times, the market size for kidney disease has seen considerable growth. There's a projection for the size to increase from $107.29 billion in 2024 to $114.74 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%.
The historical growth has been contributed by factors such as increasing chronic health problems, an aging population, genetic susceptibility, advances in medical research and education, and environmental circumstances.
What is the Forecasted Market Size and CAGR for the Kidney Disease Market?
The kidney disease market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated robust growth is on the cards for the kidney disease market in the upcoming years. The expected increment in market size will peak at $149.44 billion in 2029, escalating at a compound annual growth rate (CAGR) of 6.8%.
This surge in the forecast timeframe is attributable to factors such as management of worldwide infectious diseases, precision medicine advancements, the widespread diabetes, and obesity crisis, transformations in healthcare policies, enhanced awareness, and screening. The forecast period will also witness significant trends like the deployment of telemedicine for kidney treatment, emphasis on preventive nephrology, the emergence of home-based dialysis, progression in regenerative therapies, and adjustments in diet and nutrition.
What Key Factors and Trends are Driving the Growth of the Kidney Disease Market?
The escalating prevalence of kidney ailments is anticipated to drive the expansion of the kidney disease market. These disorders encompass a variety of conditions that impact the kidneys' operations and overall structure. Medications for kidney conditions work by reducing blood pressure and protein loss in patients, slowing kidney damage advancement, managing symptoms, and averting further complications. For example, Kidney Research UK, a charitable organization based in the UK dedicated to executing research and advocacy for bettering the understanding, prevention, and treatment of kidney diseases, reported in June 2023 that an approximated 7.19 million individuals or over 10% of the UK's population were impacted by chronic kidney disease in that year. This figure is forecasted to rise to 7.61 million individuals by 2033. Hence, the burgeoning prevalence of kidney diseases is fueling the expansion of the kidney disease market.
What are the Market Segments in the Kidney Disease Market?
The kidney disease market covered in this report is segmented –
1) By Treatment: Medication, Dialysis, Surgery, Other Treatments
2) By Indication: Acute Kidney Injury, Chronic Kidney Disease, End-Stage Renal Disease, Other Indication
3) By Route Of Administration: Oral, Parenteral
4) By End-User: Hospitals, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Medication: Antihypertensives, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Vitamin D Analogs, Immunosuppressants
2) By Dialysis: Hemodialysis, Peritoneal Dialysis
3) By Surgery: Kidney Transplant, Nephrectomy, Renal Artery Bypass, Ureteral Surgery
4) By Other Treatments: Lifestyle And Dietary Modifications, Renal Replacement Therapy, Palliative Care
Pre-Book The Kidney Disease Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Kidney Disease Market?
The use of AI-powered tools is a burgeoning trend in the kidney disease market. Companies in this sector are leveraging new technologies for better patient results and to maintain their market standing. For instance, in November 2022, a US-based healthcare startup, Carenostics, known for their expertise in AI solutions, launched their premier product which analyzes electronic health record (EHR) data for early detection of chronic kidney disease (CKD). Carenostics successfully merges AI-infused clinical decision support models with healthcare providers' electronic health record (EHR) systems. This amalgamation enables medical practitioners to accurately pinpoint patients who are at a high risk of chronic diseases, thereby allowing them to take preventative steps for improved patient health outcomes.
Who Are the Key Players in the Kidney Disease Market?
Major companies operating in the kidney disease market include:
• Pfizer Inc.
• Johnson & Johnson Ltd.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi Aventis LLC
• Bristol-Myers Squibb Company
• AstraZeneca Pharmaceuticals LP
• Abbott Laboratories
• Fresenius SE & Co. KGaA
• GlaxoSmithKline Plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Co Ltd.
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Vertex Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Kyowa Kirin Co. Ltd.
• Cipla Inc.
• Endo International plc.
• Lupin Limited
• Kissei Pharmaceutical Co. Ltd.
What are the Regional Insights into the Kidney Disease Market?
North America was the largest region in the kidney disease market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
